Evidence & regulatory context
- Mechanism
- Biologic (recombinant human alphaB-crystallin), preclinical; no matching trial identified
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryContusionC57BL/6FemaleFrom shortly after injury, with a separate arm started 6 h after injury
Model: Spinal cord contusion injury
Treatment gave sustained locomotor improvement and less secondary tissue damage, with more granulocytes and fewer inflammatory macrophages, and worked when delayed 6 h.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
